Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab + bendamustine in untreated or relapsed chronic lymphocytic leukemia
2011-005178-43Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2011
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ofatumumab and bendamustine in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by GSK. Primary endpoint: Overall response rate. Started Dec 2011; status: completed.
02
Drugs
ofatumumabbendamustine
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2011-005178-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005178-43.